Sigma-Aldrich — Investor Presentation (September 2013)
25 slides from Sigma-Aldrich's investor presentation, Sep 11, 2013
Slide 1: Sigma-Aldrich Corporation September 2013 Investor Information
© 2013 Sigma-Aldrich Co. All rights reserved. Sigma-Aldrich Corporation •September 2013 Investor Information
Slide 2: Cautionary Statements
© 2013 Sigma-Aldrich Co. All rights reserved. 2 Cautionary Statements • This presentations contains “forward-looking statements” regarding future sales, earnings, return on equity, return on invested capital, cost savings, process improvements, free cash flow, share repurchases, capital expenditures
Slide 3: Our Purpose: Enabling Science to Improve the Quality of Life
© 2013 Sigma-Aldrich Co. All rights reserved. Our Purpose 3 Enabling Science to Improve the Quality of Life The trusted and preeminent global provider to the research laboratory and targeted applied and commercial markets SAFC COMMERCIAL RESEARCH APPLIED A global leader in chemicals, biochemicals, k
Slide 4: Sigma-Aldrich in 2012
© 2013 Sigma-Aldrich Co. All rights reserved. Sigma-Aldrich in 2012 GLOBALLY BALANCED 43% Total Americas 37% Europe, Middle East, Africa 20% Asia Pacific 43% 37% 20% $2.6 Billion 53% 24% 23% 21% 79% BROAD END-MARKETS 53% Research 23% Applied 24% SAFC Commercial QUALITY PRODUCTS >170,000 Reagents and
Slide 5: Research Business Unit
© 2013 Sigma-Aldrich Co. All rights reserved. RESEARCH Business Unit Our Strategy OUR MISSION Enable researchers to advance scientific understanding and discover new therapies, drugs and advanced materials OUR CUSTOMERS Life sciences and non-profit research organizations: • Pharma & Biotech • Academ
Slide 6: Chemical Synthesis Workflow
© 2013 Sigma-Aldrich Co. All rights reserved. Chemical Synthesis Workflow 6 Planning and Preparation Synthesis and Manufacturing Purification and Characterization • Catalysts • Monomers • Specialty synthesis products • LC and GC columns • Sample collection and preparation • Reference standards Produ
Slide 7: Life Science Workflow
© 2013 Sigma-Aldrich Co. All rights reserved. Life Science Workflow DNA & RNA Proteins & Small Molecules Cells & Organisms • Protein depletion technology • SPME devices • LC and GC columns • LOPAC® small molecule library • Validated antibodies Products & Services for RESEARCH: • Reporter cell lines
Slide 8: Applied Business Unit
© 2013 Sigma-Aldrich Co. All rights reserved. 23% APPLIED Business Unit Customer Focus Our Strategy • Leverage expertise in sample prep, separation’s standards and reagents • Engage and Expand Applied Customer Base • Develop Solutions Tailored to Customer Applications • Broaden Our Capabilities – Or
Slide 9: Applied Workflow
© 2013 Sigma-Aldrich Co. All rights reserved. Applied Workflow 9 Sample Prep Detection Analysis • Reference standards • Oligonucleotides • LC and GC columns Products & Services Sigma-Aldrich Offers: • LC and GC columns • Reference standards • Protein depletion technology • Sampling devices • DNA/RNA
Slide 10: Industrial Applications
© 2013 Sigma-Aldrich Co. All rights reserved. Industrial Applications • Specialty Chemicals • Petrochemicals • Healthcare, Med Device, Contact Lenses Focus Areas: • Agricultural Products • Food Processing • Broad Chemical Offer • Bench-to-Bulk Capabilities • Custom Manufacturing • Amplification Buff
Slide 11: SAFC Commercial Business Unit
© 2013 Sigma-Aldrich Co. All rights reserved. SAFC COMMERCIAL Business Unit Life Science Products and Services Hitech Electronics Disciplined Business Model Customer Focus • Tough to make • Difficult to replicate • Critical to functionality and performance • Small percentage of total cost Supplier o
Slide 12: SAFC Commercial Offerings and Business Unit Segments
© 2013 Sigma-Aldrich Co. All rights reserved. Business Unit Segments Business Unit Initiatives Description 2012 SAFC Sales Customer Markets Biological Drugs Small Molecule Drugs LEDs Semiconductors Energy/Display Life Science Products Biopharma Materials Critical raw materials for biological drugs ~
Slide 13: Q2 2013 Highlights
© 2013 Sigma-Aldrich Co. All rights reserved. • Record quarterly sales of $681 million and diluted adjusted EPS of $1.05 • Q2 organic sales growth of 4% • Research +3% • Applied +6% • SAFC Commercial +2% • 31% year-over-year growth in free cash flow generated in the first six months of 2013 13 Q2 20
Slide 14: Research: Organic Sales Performance vs. Prior Year
© 2013 Sigma-Aldrich Co. All rights reserved. 14 Q1 Q2 (1%) 3% Academic/Govt/Hospitals (Mid-single) Low-single Pharma Flat Low-to-mid single Dealers Low-to-mid single Mid-single 2013 Overall Organic Percentage Growth:Q2 and Q1 Organic Sales Performance vs. Prior Year Business Unit: Research Improvin
Slide 15: Applied: Organic Sales Performance vs. Prior Year
© 2013 Sigma-Aldrich Co. All rights reserved. 15 Q1 Q2 3% 6% Diag/Testing High-single High-single Industrial (Low-single) Low-to-mid single 2013 Overall Organic Percentage Growth: Q2 and Q1 Organic Sales Performance vs. Prior Year Successful 1H 2013 for Applied business unit Expect continued success
Slide 16: SAFC Commercial: Organic Sales Performance vs. Prior Year
© 2013 Sigma-Aldrich Co. All rights reserved. 16 Q1 Q2 Overall Organic Percentage Growth: 3% 2% High-single High-single Hitech Electronics (Double) (Double) Life Science Services (Mid-single) Low-single Life Science Products 2013 Q2 and Q1 Organic Sales Performance vs. Prior Year Excluding weakness
Slide 17: First Six Months 2013 Financial Results
© 2013 Sigma-Aldrich Co. All rights reserved. (1) See Slide 25 for Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow. (2) Excludes Other charges. 17 First Six Months 2013 Financial Results ($ in millions, except per share amounts) YEAR-OVER-YEAR YEAR-OVER- YEAR As Reporte
Slide 18: 2013 Guidance
© 2013 Sigma-Aldrich Co. All rights reserved. 18 2013 Guidance Organic Sales Growth 2013 full-year adjusted EPS expected to be in a range of $4.05 to $4.15 1st Half 2nd Half Full Year Research 1% Low-to-mid single digit Low-to-mid single digit organic sales growth Applied 4% Mid-single digit SAFC Co
Slide 19: Q2 2013 Earnings Review Questions?
© 2013 Sigma-Aldrich Co. All rights reserved. Sigma-Aldrich Corporation Q2 2013 Earnings Review Questions?
Slide 20: Appendix: Reconciliation of GAAP to Non-GAAP Financial Measures
© 2013 Sigma-Aldrich Co. All rights reserved. Appendix •Reconciliation of GAAP to Non-GAAP Financial Measures
Slide 21: Reconciliation of Reported Net Income and Diluted EPS to Adjusted
© 2013 Sigma-Aldrich Co. All rights reserved. 2013 2012 2013 2012 Reported net income 119$ 115$ $0.98 $0.94 Other charges 8 3 0.07 0.03 Adjusted net income 127$ 118$ $1.05 $0.97 2013 2012 2013 2012 Reported net income 241$ 232$ 1.99$ 1.90$ Other charges 8 7 0.07 0.06 Adjusted net income 249$ 239$ 2.
Slide 22: Reconciliation of Reported Operating Income to Adjusted Operating Income
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Reported Operating Income to Adjusted Operating Income (Unaudited) 22 2013 2012 Reported operating income 166$ 167$ Other charges 12 4 Adjusted operating income 178$ 171$ 2013 2012 Reported operating income 332$ 339$ Other charges 12 9
Slide 23: Reconciliation of Reported Operating Income Margin to Adjusted
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Reported Operating Income Margin to Adjusted Operating Income Margin (Unaudited) 23 June 30, March 31, December 31, September 30, 2013 2013 2012 2012 Reported O perating Income Margin 24.4% 24.6% 25.0% 24.4% Other charges 1.7 % —% 0.2 %
Slide 24: Reconciliation of Reported Operating Income Margin to Adjusted
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Reported Operating Income Margin to Adjusted Operating Income Margin (Unaudited) 24 2013 2012 2013 2012 Reported operating income margin 24.4% 25.2% 24.5% 25.5% Other charges 1.7% 0.6% 0.9% 0.7% Adjusted operating income margin 26.1% 25
Slide 25: Reconciliation of Net Cash from Operating Activities to Free Cash Flow
© 2013 Sigma-Aldrich Co. All rights reserved. Reconciliation of Net Cash Provided by Operating Activities to Free Cash Flow (Unaudited) 25 2013 2012 Net cash provided by operating activities 115$ 82$ Less: Capital expenditures (24) (26) Free cash flow 91$ 56$ 2013 2012 Net cash provided by operating
Sigma-Aldrich — Investor Presentation (September 2013) on 6ix